Consensus Beam Therapeutics Inc.

Stocks

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-15 EDT			5-day change	1st Jan Change
23.22 ^USD	-3.73%		-21.71%	-16.23%

09-09	Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01:00 PM
09-08	Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints	DJ

Evolution of the Average Target: Beam Therapeutics Inc.

Evolution of the Target Price: Beam Therapeutics Inc.

Changes in Analyst Recommendations: Beam Therapeutics Inc.

1d28590e541ff22f4d.sb7Y7-zYLri3YR8CObnqJUE4vDKcE_JTZre1sz1Qyxs.3pOqlqa0QOjUVU02T9ujVh5d-mDFa5whIM_YyU19uiLAyKyg1Y9Y0PxTdA~b7bb6e10b46f8c3621bf4edef32870d5

Analysts' recommendations: Beam Therapeutics Inc.

08-05	BofA Adjusts Price Target on Beam Therapeutics to $43 From $47	MT
02-25	RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector Perform - Speculative Risk Rating	MT
02-24	Wedbush Raises Beam Therapeutics Price Target to $65 From $57, Maintains Outperform Rating	MT
02-20	Canaccord Genuity Initiates Beam Therapeutics at Buy With $74 Price Target	MT
01-07	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT
01-06	BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating	MT
25-10-09	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
25-04-03	RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk	MT
25-03-28	BofA Securities Upgrades Beam Therapeutics to Buy From Neutral	MT
25-03-10	Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target	MT
25-02-26	RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk	MT
25-01-29	Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral	MT
24-11-06	Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise	MT
24-11-06	RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating	MT
24-11-06	Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27	MT
24-10-16	Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target	MT
24-09-18	JonesTrading Initiates Beam Therapeutics at Hold	MT
24-07-23	Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy	MT
24-07-23	HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target	MT
24-07-09	RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	MT
24-02-28	Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	MT
24-02-28	RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	MT
24-02-27	Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	MT
24-01-29	JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	MT
23-12-15	BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BEAM THERAPEUTICS INC.					+116.23%
	LONZA GROUP AG					+28.82%
	REVOLUTION MEDICINES, INC.					+22.48%
	IQVIA HOLDINGS INC.					+3.99%
	BEONE MEDICINES AG					+22.32%
	CELLTRION, INC.					+50.02%
	ASCENDIS PHARMA A/S					+17.93%
	MEDPACE HOLDINGS, INC.					-2.28%
	EUROFINS SCIENTIFIC SE					+0.11%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+3.41%
	Average					+26.30%
	Weighted average by Cap.					+20.68%